Title: Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Journal: Clinical chemistry and laboratory medicine20121101
Title: Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Journal: International journal of urology : official journal of the Japanese Urological Association20120701
Title: The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Journal: Urology20120701
Title: Editorial comment.
Journal: Urology20120701
Title: [The efficacy of degarelix on LUTS (Lower urinary tract symptoms) relief in patients with prostate cancer].
Journal: Urologia20120701
Title: The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Journal: Japanese journal of clinical oncology20120601
Title: Androgen deprivation therapy: past, present and future.
Journal: BJU international20120601
Title: Short-term testosterone manipulations modulate visual recognition memory and some aspects of emotional reactivity in male rhesus monkeys.
Journal: Physiology & behavior20120515
Title: Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Journal: BJU international20120401
Title: Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial.
Journal: Reproductive biomedicine online20120201
Title: Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.
Journal: The Journal of urology20111101
Title: In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
Journal: Basic & clinical pharmacology & toxicology20110901
Title: A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Journal: The Journal of urology20110901
Title: Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
Journal: Prostate cancer and prostatic diseases20110601
Title: Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
Journal: International journal of clinical practice20110501
Title: Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
Journal: Anti-cancer drugs20110301
Title: Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
Journal: The Journal of urology20101201
Title: Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.
Journal: British journal of clinical pharmacology20101001
Title: Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Journal: BJU international20100701
Title: Degarelix. More rapid medical castration, nothing more.
Journal: Prescrire international20100601
Title: Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
Journal: European urology20100501
Title: New Drugs2010, PART 1.
Journal: Nursing20100201
Title: Evaluation of degarelix in the management of prostate cancer.
Journal: Cancer management and research20100101
Title: Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Journal: Expert review of anticancer therapy20091201
Title: Degarelix (firmagon) for prostate cancer.
Journal: The Medical letter on drugs and therapeutics20091019
Title: Degarelix.
Journal: Drugs20091001
Title: Degarelix acetate for the treatment of prostate cancer.
Journal: Drugs of today (Barcelona, Spain : 1998)20091001
Title: Degarelix for prostate cancer.
Journal: Expert opinion on investigational drugs20090601
Title: [GnRH antagonists--a new therapy option for advanced prostate cancer].
Journal: Aktuelle Urologie20090501
Title: Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
Journal: Future oncology (London, England)20090501
Title: Twenty-five year evolution of medical hormonal therapy for prostate cancer.
Journal: BJU international20090101
Title: Degarelix and its therapeutic potential in the treatment of prostate cancer.
Journal: Clinical interventions in aging20090101
Title: Degarelix: a new approach for the treatment of prostate cancer.
Journal: Neuroendocrinology20090101
Title: Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Journal: Clinical therapeutics20090101
Title: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Journal: BJU international20081201
Title: A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Journal: The Journal of urology20081101
Title: Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
Journal: European urology20081001
Title: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.
Journal: European urology20081001
Title: Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
Journal: BJU international20080601
Title: Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
Journal: Urology20080601
Title: A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20070701
Title: Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
Journal: British journal of clinical pharmacology20070601
Title: Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Journal: The Journal of pharmacology and experimental therapeutics20070301
Title: Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.
Journal: Journal of pharmacokinetics and pharmacodynamics20061001
Title: Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Journal: Journal of medicinal chemistry20060615
Title: Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
Journal: Journal of medicinal chemistry20050728
Title: Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine.
Journal: The journal of peptide research : official journal of the American Peptide Society20050201
Title: Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
Journal: The Journal of pharmacology and experimental therapeutics20020401
Title: GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.
Journal: Journal of medicinal chemistry20010201
